Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The P-Long Protocol is a multi-modal therapeutic regimen developed by Dr. Judson Brandeis for non-surgical penile lengthening and girth enhancement. The protocol integrates monthly intracavernosal injections of autologous platelet-rich plasma (PRP) with mechanical therapies, including daily penile traction using the RestoreX device and vacuum erection device (VED) therapy. The PRP component serves as a biological scaffold that releases concentrated growth factors—such as VEGF, PDGF, and TGF-beta—to promote angiogenesis and tissue regeneration within the corpora cavernosa. These biological effects are synergistically combined with mechanical stress from traction and vacuum devices to induce tissue expansion and cellular remodeling. The protocol also includes oral nitric oxide-boosting supplements (L-citrulline) to support vascular health and tissue growth. It was evaluated in an IRB-approved proof-of-concept clinical study for healthy men seeking penile enhancement.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on P-Long Protocol.